Cyberonics Seeking Federal Support For NCP Depression Pivotal Trial
This article was originally published in The Gray Sheet
Cyberonics' NCP NeuroCybernetic Prosthesis system eliminated symptoms of major depressive episodes in at least 25% of patients having completed the acute phase of a pilot study evaluating the vagus nerve stimulation therapy for major chronic depression.
You may also be interested in...
CYBERONICS' NCP DEVICE FOR EPILEPSY INITIAL COMMERCIAL IMPLANT SET FOR JULY 24; FDA APPROVAL COMES LESS THAN THREE WEEKS AFTER PANEL REVIEW
The first commercial implant of Cyberonics' NeuroCybernetic Prosthesis (NCP) system is slated for July 24 following FDA's July 16 approval of a premarket approval application for the implantable vagus nerve stimulator for treating epilepsy.
Medtechs took a long look at themselves as they rose to the challenges of COVID-19. How they responded, repurposed and regrouped to tackle the coronavirus was both sobering and uplifting. The lessons of 2020 must be integrated into the digitally-enabled health care systems of 2021 and beyond.
Top 100 Review: The Calm Before The Storm – But Some Medtechs Already Reflect The Ravages Of COVID-19
2019 saw fewer revenues-boosting major acquisitions by top-tier medtechs. Companies that reported after the calendar year-end were the first to see the consequences of the pandemic on their annual figures.